Our News on Newswise

Cancer Research Institute Awards $28.5 Million in Grants and Fellowships to Support Basic and Clinical Research in Immunology and Cancer Immunotherapy

Cancer Research Institute announced grants and fellowships of $28.5 million to scientists advancing immunology and cancer immunotherapy research
22-Jul-2021 8:00 AM EDT Add to Favorites

Cancer Research Institute Announces First Recipients of the New CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity

Cancer Research Institute announces first recipients of new fellowship program designed to promote racial diversity and inclusion in immunology and tumor immunology
22-Jul-2021 8:00 AM EDT Add to Favorites

El Cancer Research Institute Lanza Su Website Como Centro De InformacióN en EspañOl, en Su Compromiso De Liderar El Cambio Por La Igualdad Racial en El Cuidado De La Salud

El Cancer Research Institute anunció hoy que ha lanzado su primer website en español para conectar a los pacientes hispanos y sus cuidadores con la información más reciente sobre la inmunoterapia contra el cáncer y las opciones de tratamiento.
25-Jun-2021 8:00 AM EDT Add to Favorites

Cancer Research Institute (CRI) Launches Spanish-Language Resource Hub in Its Commitment to Lead the Change in Racial Health Equity

The Cancer Research Institute (CRI) announced today that is has launched its first-ever Spanish-language information hub to connect Hispanic patients and caregivers with the latest cancer immunotherapy research and treatment options.
25-Jun-2021 8:00 AM EDT Add to Favorites

Cancer Research Institute Celebrates Ninth Annual Cancer Immunotherapy Month™

Cancer Research Institute celebrates progress in cancer immunotherapy research, announces new initiatives aimed at addressing racial and ethnic disparities in cancer treatment and academic research, during ninth annual Cancer Immunotherapy Month...
25-May-2021 7:00 PM EDT Add to Favorites

Cancer Research Institute and RevImmune Announce Dosing of First Patient in New Phase 2 Study Assessing Therapeutic Benefit of Interleukin-7 in Patients with Cancer and COVID-19

New immunotherapy approach to treating cancer patients with COVID-19 aims to reduce risk of severe COVID-19 symptoms by reinvigorating patients' cellular immune responses
30-Mar-2021 7:00 AM EDT Add to Favorites

Newswise: JOT-2019.jpg

Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey Receives Inaugural Tara Withington Public Service Award from the Society for Immunotherapy of Cancer

Award honors individuals and organizations that foster and enhance the field of cancer immunotherapy through increasing public understanding, awareness, research efforts, and/or funding
11-Nov-2020 4:00 PM EST Add to Favorites

Newswise: NRDDCRIPD-1PD-L1GlobalClinicalOncologyLandscapeUpdate2020fig4wIQVIA.jpg

Combination Drug Strategies Gain Ground in Global Immuno-Oncology Pipeline of PD-1 and PD-L1 Clinical Trials, New Report from Cancer Research Institute Reveals

Analysis update by the nonprofit Cancer Research Institute reveals dramatic growth in PD-1/PD-L1 monoclonal antibody combination cancer treatment strategies in global clinical trial pipeline
11-Nov-2020 11:35 AM EST Add to Favorites

See All News

Our Experts on Newswise

Expert Available for Commentary on Recent FDA Analysis of TNF Blockers

The FDA announced on Aug 4 2009 that tumor necrosis factor (TNF) blockers used in the treatment of immune disorders carry an increased risk of lymphoma and other cancers in children and adolescents. The discoverer of TNF-alpha, Lloyd J. Old, M.D., a...
7-Aug-2009 9:00 AM EDT

PROVENGE Cancer Vaccine Heralds New Dawn in Cancer Therapy

Dendreon's PROVENGE for the treatment of advanced prostate cancer is the first active cellular immunotherapy to prolong patient survival, according to data from a pivotal phase III clinical trial announced at yesterday's AUA annual meeting in...
29-Apr-2009 11:20 AM EDT

See All Experts

Our YouTube Videos


The mission of the Cancer Research Institute is to save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer.


Brian Brewer
Director of Marketing and Communications



Elliot Fox